A Phase 1 interventional study of Durvalumab and Tremelimumab in Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma, sponsored by AstraZeneca. Completed at 16 sites in 5 countries. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck — none open to participants now, 3 under way, none of them phase 3. durvalumab · Squamous Cell Carcinoma of Head and Neck.
Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, this one is the 5th largest by enrollment, is one of 7 that started in 2018, is one of 7 in phase 1, and was the 13th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →None of the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 3
First in 2013; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 40 across the 20 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca: 4 open now, 6 under way, 2 of them phase 3. Of 15 finished, 5 (33%) have results posted.
Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 1, and was the 13th registered.
AstraZeneca’s Squamous Cell Carcinoma of Head and Neck studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Among AstraZeneca’s 22 in Squamous Cell Carcinoma of Head and Neck:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
This study will initially treat up to approximately 300 patients with advanced solid tumors at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity (DLT) assessment phase (Part A) and an expansion phase (Part B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
Drug: Durvalumab · Drug: Cisplatin (dose level 4) · Radiation: External beam radiation (dose level 1)
Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
Drug: Durvalumab · Drug: Etoposide (dose level 1) · Radiation: External beam radiation (dose level 2) · Drug: Cisplatin (dose level 1)
Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
Drug: Durvalumab · Drug: Carboplatin (dose level 1) · Drug: Paclitaxel · Radiation: External beam radiation (dose level 2)
Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
Drug: Durvalumab · Drug: Carboplatin (dose level 2) · Drug: Pemetrexed · Radiation: External beam radiation (dose level 2) · Drug: Cisplatin (dose level 2)
Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
Drug: Durvalumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (standard)
Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
Drug: Durvalumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (hyperfractionated)
Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (standard)
Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (hyperfractionated)
IV (intravenous)
Also known as: MEDI4736
IV
IV
IV
IV
IV
IV
IV
IV
IV
radiation therapy
radiation therapy
radiation therapy
IV
IV
radiation therapy
Number of subjects with Dose Limiting Toxicities (DLTs)
Time frame: From first dose of durvalumab until 28 days after completion of radiation therapy
Number of subjects with Adverse Events (AEs)
Time frame: From first dose of durvalumab up to 90 days after the last dose of study treatment
Progression-free survival (PFS)
Time frame: From first dose until the date of objective disease progression or death, in the absence of progression at 12, 18 and 24 months, up to 4 years.
Overall Survival (OS)
Time frame: From first dose until death due to any cause through study completion, up to 4 years
Objective response rate (ORR)
Number (%) of patients with an overall response of complete response (CR) or partial response (PR).
Time frame: From first dose until disease progression, or the last evaluable assessment in the absence of progression, assessed up to 4 years.
Best objective response (BoR)
The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression.
Time frame: From first dose until disease progression, or the last evaluable assessment in the absence of progression, assessed up to 4 years.
Duration of response (DoR)
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.
Time frame: From first dose until disease progression, or death, in the absence of progression, assessed up to 4 years.
Disease control rate (DCR)
Time frame: From first dose until disease progression, at 18 weeks and 48 weeks.
Disease-free survival (DFS)
Time frame: From first dose until disease progression or death, in the absence of progression at 12, 18 and 24 months, assessed up to 4 years.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Dec 2020, 31 months.
Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's 31 months is below that.
Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab · Cisplatin · Carboplatin · Etoposide · Paclitaxel · Pemetrexed
Squamous Cell Carcinoma of Head and Neck →